Amgen Inc. (AMGN) Stake Decreased by Candriam Luxembourg S.C.A.
Candriam Luxembourg S.C.A. lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 15.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 588,715 shares of the medical research company’s stock after selling 111,618 shares during the period. Amgen accounts for approximately 2.3% of Candriam Luxembourg S.C.A.’s holdings, making the stock its largest position. Candriam Luxembourg S.C.A. owned 0.08% of Amgen worth $89,577,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Oakworth Capital Inc. increased its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN increased its stake in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC increased its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC increased its stake in Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the period. Finally, Evanson Asset Management LLC acquired a new stake in Amgen during the second quarter worth approximately $211,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.36% during mid-day trading on Friday, hitting $167.50. The stock had a trading volume of 1,679,823 shares. The firm has a market cap of $125.35 billion, a price-to-earnings ratio of 17.14 and a beta of 0.94. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The company has a 50-day moving average of $170.75 and a 200 day moving average of $161.82.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.57 earnings per share. On average, equities research analysts forecast that Amgen Inc. will post $11.35 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.39%. Amgen’s dividend payout ratio (DPR) is 40.90%.
A number of equities research analysts have commented on AMGN shares. BMO Capital Markets reissued an “outperform” rating and issued a $186.00 target price on shares of Amgen in a report on Thursday, June 9th. Leerink Swann reissued a “market perform” rating and issued a $186.00 target price on shares of Amgen in a report on Thursday, June 9th. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a report on Monday, June 13th. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $202.00 target price on shares of Amgen in a report on Wednesday, June 15th. Finally, Sanford C. Bernstein started coverage on Amgen in a report on Wednesday, June 29th. They issued a “market perform” rating and a $161.00 target price for the company. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.